DDInter1323 DDInter1435
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Octreotide {u} (Compound) resembles {v} (Compound) Polymyxin B
Octreotide {u} (Compound) resembles {v} (Compound) Bacitracin
Octreotide {u} (Compound) treats {v} (Disease) thymus cancer
Octreotide {u} (Compound) binds {v} (Gene) SSTR2
Octreotide {u} (Compound) palliates {v} (Disease) type 1 diabetes mellitus
Octreotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Octreotide {u} (Compound) causes {v} (Side Effect) Arthropathy
Octreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Octreotide (Compound) resembles Polymyxin B (Compound)
Octreotide (Compound) resembles Bacitracin (Compound)
Octreotide (Compound) treats thymus cancer (Disease)
Octreotide (Compound) binds SSTR2 (Gene)
Octreotide (Compound) palliates type 1 diabetes mellitus (Disease)
Octreotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Octreotide (Compound) causes Arthropathy (Side Effect)
Octreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human